SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
BOSTON, March 01, 2018 -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a conference call on Tuesday, March 6, 2018 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2017.
Participants may access the call by dialing (844) 824-7428 in the U.S. or (973) 500-2177 outside the U.S. and referencing conference ID number 7184949. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 7:30 p.m. ET on March 6, 2018 through March 13, 2018 by dialing (855) 859-2056 in the U.S. or (404) 537-3406 outside the U.S. To access the replay please provide conference ID number 7184949.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome and liver diseases. The company’s lead product candidate is ZGN-1061, a MetAP2 inhibitor in Phase 2 clinical development with unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. In 2018, Zafgen plans to file an investigational new drug (IND) application with the U.S. FDA and initiate Phase 1 clinical trials for ZGN-1258, its new molecule for the treatment of Prader-Willi syndrome and potential other rare and serious forms of obesity. Learn more at www.zafgen.com.
Media/Investor Relations Contacts:
Zafgen, Inc.
Patricia Allen
Chief Financial Officer
617-648-9792
Media
Krystle Gibbs
Ten Bridge Communications
[email protected]
508-479-6358
Investors
John Woolford
Westwicke Partners
[email protected]
443-213-0506
